BTLS Stock Overview
Biotalys NV, an agricultural technology company, discovers and develops novel biological products in Belgium and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Biotalys NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.05 |
| 52 Week High | €6.70 |
| 52 Week Low | €1.62 |
| Beta | 0.97 |
| 1 Month Change | -2.56% |
| 3 Month Change | -33.70% |
| 1 Year Change | -53.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| BTLS | BE Chemicals | BE Market | |
|---|---|---|---|
| 7D | -2.9% | -0.2% | 2.4% |
| 1Y | -53.1% | -46.4% | -2.8% |
Return vs Industry: BTLS underperformed the Belgian Chemicals industry which returned -46.3% over the past year.
Return vs Market: BTLS underperformed the Belgian Market which returned -3.3% over the past year.
Price Volatility
| BTLS volatility | |
|---|---|
| BTLS Average Weekly Movement | 8.9% |
| Chemicals Industry Average Movement | 3.9% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.7% |
| 10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: BTLS's share price has been volatile over the past 3 months.
Volatility Over Time: BTLS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 75 | Kevin Helash | www.biotalys.com |
Biotalys NV, an agricultural technology company, discovers and develops novel biological products in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and anthracnose in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; and BIOFUN-4 targeting oomycetes in fruits and vegetables.
Biotalys NV Fundamentals Summary
| BTLS fundamental statistics | |
|---|---|
| Market cap | €98.08m |
| Earnings (TTM) | -€20.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs BTLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTLS income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €20.51m |
| Earnings | -€20.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 11.3% |
How did BTLS perform over the long term?
See historical performance and comparison